TAK vs. ALNY, GMAB, BMRN, TEVA, BGNE, VTRS, SRPT, RDY, UTHR, and ZTS
Should you be buying Takeda Pharmaceutical stock or one of its competitors? The main competitors of Takeda Pharmaceutical include Alnylam Pharmaceuticals (ALNY), Genmab A/S (GMAB), BioMarin Pharmaceutical (BMRN), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Viatris (VTRS), Sarepta Therapeutics (SRPT), Dr. Reddy's Laboratories (RDY), United Therapeutics (UTHR), and Zoetis (ZTS). These companies are all part of the "pharmaceutical preparations" industry.
Takeda Pharmaceutical (NYSE:TAK) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.
Alnylam Pharmaceuticals received 990 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 76.17% of users gave Alnylam Pharmaceuticals an outperform vote while only 56.82% of users gave Takeda Pharmaceutical an outperform vote.
Takeda Pharmaceutical has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500.
Takeda Pharmaceutical has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Alnylam Pharmaceuticals had 13 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 21 mentions for Alnylam Pharmaceuticals and 8 mentions for Takeda Pharmaceutical. Alnylam Pharmaceuticals' average media sentiment score of 0.45 beat Takeda Pharmaceutical's score of -0.14 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media.
Takeda Pharmaceutical has a net margin of 6.90% compared to Alnylam Pharmaceuticals' net margin of -16.58%. Takeda Pharmaceutical's return on equity of 12.57% beat Alnylam Pharmaceuticals' return on equity.
Takeda Pharmaceutical currently has a consensus target price of $14.00, suggesting a potential upside of 4.63%. Alnylam Pharmaceuticals has a consensus target price of $216.19, suggesting a potential upside of 42.82%. Given Alnylam Pharmaceuticals' higher probable upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Takeda Pharmaceutical.
Summary
Alnylam Pharmaceuticals beats Takeda Pharmaceutical on 9 of the 17 factors compared between the two stocks.
Get Takeda Pharmaceutical News Delivered to You Automatically
Sign up to receive the latest news and ratings for TAK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TAK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Takeda Pharmaceutical Competitors List
Related Companies and Tools
